Thus, apart from impairing VEGF signalling, cabozantinib inhibits a variety of receptor tyrosine kinases including MET and TAM kinases (TYRO3, AXL, MER) involved in tumour growth, metastasis, and therapeutic resistance with a role in immunosuppression [11–13]. Here, AXL is linked to neoplasm.